Abstract | BACKGROUND: Drug-resistance and therapy failure due to drug-drug interactions are the main challenges in current treatment against Human Immunodeficiency Virus ( HIV) infection. As such, there is a continuous need for the development of new and more potent anti-HIV drugs. Here we established a high-throughput screen based on the highly permissive TZM-bl cell line to identify novel HIV inhibitors. The assay allows discriminating compounds acting on early and/or late steps of the HIV replication cycle. RESULTS: The platform was used to screen a unique library of secondary metabolites derived from myxobacteria. Several hits with good anti-HIV profiles were identified. Five of the initial hits were tested for their antiviral potency. Four myxobacterial compounds, sulfangolid C, soraphen F, epothilon D and spirangien B, showed EC50 values in the nM range with SI > 15. Interestingly, we found a high amount of overlapping hits compared with a previous screen for Hepatitis C Virus (HCV) using the same library. CONCLUSION: The unique structures and mode-of-actions of these natural compounds make myxobacteria an attractive source of chemicals for the development of broad-spectrum antivirals. Further biological and structural studies of our initial hits might help recognize smaller drug-like derivatives that in turn could be synthesized and further optimized.
|
Authors | Javier P Martinez, Bettina Hinkelmann, Eric Fleta-Soriano, Heinrich Steinmetz, Rolf Jansen, Juana Diez, Ronald Frank, Florenz Sasse, Andreas Meyerhans |
Journal | Microbial cell factories
(Microb Cell Fact)
Vol. 12
Pg. 85
(Sep 24 2013)
ISSN: 1475-2859 [Electronic] England |
PMID | 24063434
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Anti-HIV Agents
(isolation & purification, pharmacology)
- Drug Resistance
- High-Throughput Screening Assays
(methods)
- Humans
- Myxococcales
(chemistry)
|